<DOC>
	<DOCNO>NCT02134288</DOCNO>
	<brief_summary>Currently look individual receive kidney transplant , experience delay graft function ( DGF ) , meet criterion study participation .</brief_summary>
	<brief_title>Belatacept Renal Transplant Recipients With Delayed Graft Function</brief_title>
	<detailed_description>Patients undergo kidney transplantation require long term immunosuppressive therapy ( therapy reduce body 's ability respond anything foreign ) prevent damage graft , experience delay graft function ( DGF , condition transplant kidney function properly ) transplantation . This study conduct determine kidney transplant recipient delay graft function ( DGF ) switch immunosuppressive regimen belatacept mycophenolate steroid recover delay graft function ( DGF ) less time ( could potentially low risk rejection associate delay graft function ) kidney transplant recipient delay graft function ( DGF ) remain current standard immunosuppressive regimen ( standard care ) .</detailed_description>
	<mesh_term>Delayed Graft Function</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>1 . Signed Written Informed Consent 2 . Deceased donor renal transplant recipient 3 . Men woman , age 1860 year age 1 . Seronegative unknown EBV serostatus 2 . Patients unwilling incapable providing informed consent . 3 . Patients active tuberculosis positive TB test without evidence infection treatment . 4 . Patients demonstrate acute rejection first biopsy evaluation delay graft function ; Second transplant multiple organ transplant ; patient 12 day post renal transplant prior enrollment 5 . Evidence Sepsis clinical indicator deem clinically contraindicate study enrollment primary physician 6 . Inadequate vein access receive monthly IV infusion 7 . Prior proven allergy severe adverse drug reaction mycophenolate , steroid Belatacept prevent therapy . 8 . Pregnant woman woman child bear age willing commit dual contraception prophylaxis 9 . Use alemtuzumab ( Campath 1H© ) , basilixumab ( Simulect© ) daclizumab ( Zenapax© ) permit protocol ; Use immunosuppressive agent must limit specify protocol . 10 . Prisoners subject involuntarily incarcerate . 11 . Subjects compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness . 12 . Presensitized patient alloscreen antibody level 80 % class I class II</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Dialysis</keyword>
	<keyword>Kidney Transplant</keyword>
	<keyword>immunosuppressive therapy</keyword>
	<keyword>Delayed Graft Function</keyword>
	<keyword>Belatacept</keyword>
</DOC>